.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The ETHOS trial examined whether inhaled triple therapy with budesonide, glycopyrrolate and formoterol could improve outcomes in symptomatic patients with moderate-to-very-severe COPD who had a history of exacerbations. In this prespecified mortality analysis, the investigators used final vital-status information from the 52-week randomized trial. The higher-dose budesonide triple-therapy regimen was associated with fewer deaths than glycopyrrolate/formoterol dual therapy. The comparison with budesonide/formoterol did not show a statistically significant mortality difference, and the lower-dose triple-therapy regimen did not demonstrate a significant mortality reduction versus the dual comparators. The authors therefore framed the mortality signal as supportive evidence for the role of triple therapy in an appropriately selected COPD population rather than proof that every patient should receive inhaled corticosteroids. For practice, the paper reinforces a broader point from the conference's COPD track: treatment choices should be linked to exacerbation risk, symptoms, lung function and likely treatment benefit, while weighing inhaled corticosteroid-related risks such as pneumonia. It is especially useful when discussing what additional evidence can be drawn from the ETHOS program beyond exacerbation prevention.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The ETHOS trial examined whether inhaled triple therapy with budesonide, glycopyrrolate and formoterol could improve outcomes in symptomatic patients with moderate-to-very-severe COPD who had a history of exacerbations. In this prespecified mortality analysis, the investigators used final vital-status information from the 52-week randomized trial. The higher-dose budesonide triple-therapy regimen was associated with fewer deaths than glycopyrrolate/formoterol dual therapy. The comparison with budesonide/formoterol did not show a statistically significant mortality difference, and the lower-dose triple-therapy regimen did not demonstrate a significant mortality reduction versus the dual comparators. The authors therefore framed the mortality signal as supportive evidence for the role of triple therapy in an appropriately selected COPD population rather than proof that every patient should receive inhaled corticosteroids. For practice, the paper reinforces a broader point from the conference's COPD track: treatment choices should be linked to exacerbation risk, symptoms, lung function and likely treatment benefit, while weighing inhaled corticosteroid-related risks such as pneumonia. It is especially useful when discussing what additional evidence can be drawn from the ETHOS program beyond exacerbation prevention.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
